open access
Correlation of [18F]FDG PET activity with expressions of Ki-67 in non-small-cell lung cancer
, 1, 1, 2
Affiliations- Department of Pathology, Konya City Hospital, Konya, Turkey
- Department of Nuclear medicine, Konya City Hospital, Konya, Turkey
open access
Abstract
Background: Lung carcinoma is the most commonly diagnosed cancer throughout the world and is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for up to 80% of newly diagnosed lung cancer cases. This study aimed to investigate the relationship between Ki-67 proliferation index (PI) and the maximum standardized uptake value (SUVmax) obtained from [18F]FDG PET/CT in NSCLCs and whether prognosis was predicted with SUVmax values. Material and methods: This retrospective study included biopsy and resection materials of 41 patients, who were examined in the pathology laboratory of Konya Training and Research Hospital between January 2010 and December 2019, and diagnosed with NSCLC, and whose [18F]FDG PET/CT images were present. Results: There was no significant difference between histopathological subtypes in terms of age (p = 0.077), Ki-67 PI (p = 0.454), and SUVmax (p = 0.143). No correlation was observed between Ki-67 PI and SUVmax values obtained from [18F]FDG PET/CT (p = 0.338, r = 0.153). There was no significant correlation between Ki-67 PI and tumor diameter (p = 0.531). The SUVmax value was found to be lower (12.78 ± 6.14) in tumors measuring ≤ 2.5 in diameter and higher (18.46 ± 7.81) in tumors measuring > 2.5 cm (p = 0.027). Metastases not proven histopathologically but detected in [18F]FDG PET/CT were found to have no significant correlation with Ki-67 and SUVmax values (p = 0.881, p = 0.837). Conclusions: This study showed that there was no significant relationship between Ki-67 PI and SUVmax value obtained from [18F]FDG PET/CT in NSCLC tumors.
Abstract
Background: Lung carcinoma is the most commonly diagnosed cancer throughout the world and is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for up to 80% of newly diagnosed lung cancer cases. This study aimed to investigate the relationship between Ki-67 proliferation index (PI) and the maximum standardized uptake value (SUVmax) obtained from [18F]FDG PET/CT in NSCLCs and whether prognosis was predicted with SUVmax values. Material and methods: This retrospective study included biopsy and resection materials of 41 patients, who were examined in the pathology laboratory of Konya Training and Research Hospital between January 2010 and December 2019, and diagnosed with NSCLC, and whose [18F]FDG PET/CT images were present. Results: There was no significant difference between histopathological subtypes in terms of age (p = 0.077), Ki-67 PI (p = 0.454), and SUVmax (p = 0.143). No correlation was observed between Ki-67 PI and SUVmax values obtained from [18F]FDG PET/CT (p = 0.338, r = 0.153). There was no significant correlation between Ki-67 PI and tumor diameter (p = 0.531). The SUVmax value was found to be lower (12.78 ± 6.14) in tumors measuring ≤ 2.5 in diameter and higher (18.46 ± 7.81) in tumors measuring > 2.5 cm (p = 0.027). Metastases not proven histopathologically but detected in [18F]FDG PET/CT were found to have no significant correlation with Ki-67 and SUVmax values (p = 0.881, p = 0.837). Conclusions: This study showed that there was no significant relationship between Ki-67 PI and SUVmax value obtained from [18F]FDG PET/CT in NSCLC tumors.
Keywords
non-small cell lung cancer; Ki-67; PET/CT
About this articleTitle
Correlation of [18F]FDG PET activity with expressions of Ki-67 in non-small-cell lung cancer
Journal
Issue
Article type
Research paper
Pages
73-77
Published online
2022-06-29
Page views
4338
Article views/downloads
447
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2022;25(2):73-77.
Keywords
non-small cell lung cancer
Ki-67
PET/CT
Authors
Ilknur Kucukosmanoglu
Meryem Ilkay Eren Karanis
Yasar Unlu
Mustafa Erol
References (15)- Ozgül MA, Kirkil G, Seyhan EC, et al. The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer. Multidiscip Respir Med. 2013; 8(1): 69.
- Warth A, Cortis J, Soltermann A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer. 2014; 111(6): 1222–1229.
- Sauter AW, Winterstein S, Spira D, et al. Multifunctional Profiling of Non–Small Cell Lung Cancer Using 18F-FDG PET/CT and Volume Perfusion CT. J Nuc Med. 2012; 53(4): 521–529.
- Hochhegger B, Alves GR, Irion KL, et al. PET/CT imaging in lung cancer: indications and findings. J Bras Pneumol. 2015; 41(3): 264–274.
- Vesselle H, Salskov A, Turcotte E, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008; 3(9): 971–978.
- Ambrosini V, Nicolini S, Caroli P, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol. 2012; 81(5): 988–1001.
- Ma W, Wang M, Li X, et al. Quantitative F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer. Oncol Lett. 2018; 16(4): 4129–4136.
- Chirieac LR. Ki-67 expression in pulmonary tumors. Transl Lung Cancer Res. 2016; 5(5): 547–551.
- Bedir R, Yusufoğlu B, Bilir C, et al. Relationship Between The [18F]FDG Uptake with Ki-67 and P53 Expression in Patients with Lung Cancer: A Clino-Pathologic Study. J hum rhythm. 2016; 2(3): 126–33.
- Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1): 13–20.
- Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004; 91(12): 2018–2025.
- Jakobsen JN, Sørensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013; 79(1): 1–7.
- Surov A, Meyer HJ, Wienke A. Standardized Uptake Values Derived from F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1 but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53. Contrast Media Mol Imaging. 2018.
- Spyratos F, Ferrero-Poüs M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer. 2002; 94(8): 2151–2159.
- Ishibashi N, Maebayashi T, Aizawa T, et al. Correlation between the Ki-67 proliferation index and response to radiation therapy in small cell lung cancer. Radiat Oncol. 2017; 12(1): 16.
